NeuBase Therapeutics Inc
F:O7PA
NeuBase Therapeutics Inc
Other Liabilities
NeuBase Therapeutics Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NeuBase Therapeutics Inc
F:O7PA
|
Other Liabilities
$4.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Liabilities
$31.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
24%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Liabilities
$24.6B
|
CAGR 3-Years
69%
|
CAGR 5-Years
19%
|
CAGR 10-Years
31%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Liabilities
$5.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Liabilities
$3.1B
|
CAGR 3-Years
43%
|
CAGR 5-Years
37%
|
CAGR 10-Years
51%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Liabilities
$2.2B
|
CAGR 3-Years
47%
|
CAGR 5-Years
24%
|
CAGR 10-Years
11%
|
|
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
See Also
What is NeuBase Therapeutics Inc's Other Liabilities?
Other Liabilities
4.8m
USD
Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Other Liabilities amounts to 4.8m USD.
What is NeuBase Therapeutics Inc's Other Liabilities growth rate?
Other Liabilities CAGR 1Y
-10%
Over the last year, the Other Liabilities growth was -10%.
